However, additional studies demonstrated that, in addition to ovarian cancer, HE4 expression was not only in normal tissues but also in both benign and malignant diseases to varying degrees [17], which has serious doubts about the specificity of HE4 and its use as a biomarker for this cancer [18]. This evidence concerns the gene WFDC2 and ovarian carcinoma.